Literature DB >> 29789325

Genomic-Epidemiologic Evidence That Estrogens Promote Breast Cancer Development.

Fritz F Parl1, Philip S Crooke2, W Dale Plummer3, William D Dupont3.   

Abstract

Background: Estrogens are a prime risk factor for breast cancer, yet their causal relation to tumor formation remains uncertain. A recent study of 560 breast cancers identified 82 genes with 916 point mutations as drivers in the genesis of this malignancy. Because estrogens play a major role in breast cancer development and are also known to regulate the expression of numerous genes, we hypothesize that the 82 driver genes are likely to be influenced by estrogens, such as 17ß-estradiol (E2), and the estrogen receptor ESR1 (ERα). Because different types of tumors are characterized by unique sets of cancer driver genes, we also argue that the fraction of driver genes regulated by E2-ESR1 is lower in malignancies not associated with estrogens, e.g., acute myeloid leukemia (AML).
Methods: We performed a literature search of each driver gene to determine its E2-ESR1 regulation.
Results: Fifty-three of the 82 driver genes (64.6%) identified in breast cancers showed evidence of E2-ESR1 regulation. In contrast, only 19 of 54 mutated driver genes (35.2%) identified in AML were linked to E2-ESR1. Among the 916 driver mutations found in breast cancers, 813 (88.8%) were linked to E2-ESR1 compared with 2,046 of 3,833 in AML (53.4%).Conclusions: Risk assessment revealed that mutations in estrogen-regulated genes are much more likely to be associated with elevated breast cancer risk, while mutations in unregulated genes are more likely to be associated with AML.Impact: These results increase the plausibility that estrogens promote breast cancer development. Cancer Epidemiol Biomarkers Prev; 27(8); 899-907. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29789325      PMCID: PMC6072561          DOI: 10.1158/1055-9965.EPI-17-1174

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  61 in total

Review 1.  Functional proteomics of the epigenetic regulators ASXL1, ASXL2 and ASXL3: a convergence of proteomics and epigenetics for translational medicine.

Authors:  Masaru Katoh
Journal:  Expert Rev Proteomics       Date:  2015-04-03       Impact factor: 3.940

2.  Genome-wide analysis of estrogen receptor binding sites.

Authors:  Jason S Carroll; Clifford A Meyer; Jun Song; Wei Li; Timothy R Geistlinger; Jérôme Eeckhoute; Alexander S Brodsky; Erika Krasnickas Keeton; Kirsten C Fertuck; Giles F Hall; Qianben Wang; Stefan Bekiranov; Victor Sementchenko; Edward A Fox; Pamela A Silver; Thomas R Gingeras; X Shirley Liu; Myles Brown
Journal:  Nat Genet       Date:  2006-10-01       Impact factor: 38.330

3.  Estrogen expands breast cancer stem-like cells through paracrine FGF/Tbx3 signaling.

Authors:  Christine M Fillmore; Piyush B Gupta; Jenny A Rudnick; Silvia Caballero; Patricia J Keller; Eric S Lander; Charlotte Kuperwasser
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-22       Impact factor: 11.205

4.  Two-stage model for carcinogenesis: Epidemiology of breast cancer in females.

Authors:  S H Moolgavkar; N E Day; R G Stevens
Journal:  J Natl Cancer Inst       Date:  1980-09       Impact factor: 13.506

5.  FOXP1, an estrogen-inducible transcription factor, modulates cell proliferation in breast cancer cells and 5-year recurrence-free survival of patients with tamoxifen-treated breast cancer.

Authors:  Takashi Shigekawa; Nobuhiro Ijichi; Kazuhiro Ikeda; Kuniko Horie-Inoue; Chikako Shimizu; Shigehira Saji; Kenjiro Aogi; Hitoshi Tsuda; Akihiko Osaki; Toshiaki Saeki; Satoshi Inoue
Journal:  Horm Cancer       Date:  2011-10       Impact factor: 3.869

6.  Identification of the MLL2 complex as a coactivator for estrogen receptor alpha.

Authors:  Rigen Mo; Sambasiva M Rao; Yi-Jun Zhu
Journal:  J Biol Chem       Date:  2006-04-07       Impact factor: 5.157

7.  Estrogen inhibits ATR signaling to cell cycle checkpoints and DNA repair.

Authors:  Ali Pedram; Mahnaz Razandi; Albert J Evinger; Eva Lee; Ellis R Levin
Journal:  Mol Biol Cell       Date:  2009-05-28       Impact factor: 4.138

Review 8.  Cross-talk between estradiol receptor and EGFR/IGF-IR signaling pathways in estrogen-responsive breast cancers: focus on the role and impact of proteoglycans.

Authors:  Spyros S Skandalis; Nikolaos Afratis; Gianna Smirlaki; Dragana Nikitovic; Achilleas D Theocharis; George N Tzanakakis; Nikos K Karamanos
Journal:  Matrix Biol       Date:  2013-09-21       Impact factor: 11.583

9.  Tyrosine phosphatase Shp2 mediates the estrogen biological action in breast cancer via interaction with the estrogen extranuclear receptor.

Authors:  Jun Li; Yujia Kang; Longgang Wei; Wenjie Liu; Yingpu Tian; Baozhen Chen; Xiandong Lin; Yang Li; Gen-Sheng Feng; Zhongxian Lu
Journal:  PLoS One       Date:  2014-07-21       Impact factor: 3.240

10.  GATA3 acts upstream of FOXA1 in mediating ESR1 binding by shaping enhancer accessibility.

Authors:  Vasiliki Theodorou; Rory Stark; Suraj Menon; Jason S Carroll
Journal:  Genome Res       Date:  2012-11-21       Impact factor: 9.043

View more
  3 in total

Review 1.  Estrogen Receptors Alpha and Beta in Acute Myeloid Leukemia.

Authors:  Alessia Roma; Paul A Spagnuolo
Journal:  Cancers (Basel)       Date:  2020-04-08       Impact factor: 6.639

2.  Activation of GPER by E2 promotes proliferation, invasion and migration of breast cancer cells by regulating the miR-124/CD151 pathway.

Authors:  Huaicheng Yang; Congyu Wang; Heqiang Liao; Qi Wang
Journal:  Oncol Lett       Date:  2021-03-31       Impact factor: 2.967

3.  A human MMTV-like betaretrovirus linked to breast cancer has been present in humans at least since the copper age.

Authors:  Francesca Lessi; Nicole Grandi; Chiara Maria Mazzanti; Prospero Civita; Cristian Scatena; Paolo Aretini; Pasquale Bandiera; Antonio Fornaciari; Valentina Giuffra; Gino Fornaciari; Antonio Giuseppe Naccarato; Enzo Tramontano; Generoso Bevilacqua
Journal:  Aging (Albany NY)       Date:  2020-07-31       Impact factor: 5.682

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.